TriSalus Life Sciences, Inc.
General ticker "TLSI" information:
- Sector: Health Care
- Industry: Medical - Devices
- Capitalization: $237.4M (TTM average)
TriSalus Life Sciences, Inc. does not follow the US Stock Market performance with the rate: -3.3%.
Estimated limits based on current volatility of 4.8%: low 3.96$, high 4.36$
Factors to consider:
- Total employees count: 102 (-7.3%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Limited operating history, Inability to raise capital, Reimbursement failure, Market competition, Regulatory and compliance
- Price in estimated range
- Earnings for 6 months up through Q2 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [3.91$, 10.63$]
- 2026-12-31 to 2027-12-31 estimated range: [3.07$, 8.69$]
Financial Metrics affecting the TLSI estimates:
- Negative: with PPE of -3.9 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Net income
- Negative: negative Industry operating income (median)
- Positive: -1.23 < Investing cash flow per share per price, % of -0.32
- Positive: Industry inventory ratio change (median), % of 0.70 <= 1.15
- Negative: Shareholder equity ratio, % of -95.84 <= 7.04
Short-term TLSI quotes
Long-term TLSI plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $18.51MM | $29.43MM | $45.15MM |
| Operating Expenses | $72.99MM | $65.60MM | $72.10MM |
| Operating Income | $-54.48MM | $-36.16MM | $-26.95MM |
| Non-Operating Income | $-4.88MM | $6.13MM | $-12.27MM |
| Interest Expense | $0.02MM | $3.09MM | $5.54MM |
| R&D Expense | $29.84MM | $17.69MM | $14.96MM |
| Income(Loss) | $-59.35MM | $-30.04MM | $-39.22MM |
| Taxes | $0.01MM | $0.01MM | $0.01MM |
| Net Income(Loss)* | $-59.36MM | $-30.05MM | $-39.23MM |
| Stockholders Equity | $-27.07MM | $-25.89MM | $-33.86MM |
| Inventory | $2.54MM | $4.05MM | $3.08MM |
| Assets | $24.60MM | $23.97MM | $35.33MM |
| Operating Cash Flow | $-50.58MM | $-40.84MM | $-18.01MM |
| Capital expenditure | $0.59MM | $0.34MM | $0.92MM |
| Investing Cash Flow | $-1.59MM | $-0.34MM | $-0.84MM |
| Financing Cash Flow | $54.63MM | $37.94MM | $30.76MM |
| Earnings Per Share** | $-2.24 | $-1.13 | $-1.04 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.